KATRINA CHAMBERS: Open Payments
NPI 1710695143 · ENCINITAS, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,784 in 189 payments from 21 companies in 2025. Trend: 2023 $1,502 · 2024 $3,927 · 2025 $4,784
Food & beverage: $4,700Education: $84
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 39 | $1,083 |
| Janssen Biotech, Inc. | 31 | $720 |
| GENZYME CORPORATION | 11 | $490 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 17 | $466 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $281 |
| Madrigal Pharmaceuticals | 14 | $245 |
| Celltrion USA Inc. | 10 | $211 |
| Lilly USA, LLC | 7 | $209 |
| QOL Medical, LLC | 12 | $193 |
| Aimmune Therapeutics, Inc. | 7 | $147 |
Products named: TREMFYA, DUPIXENT, XIFAXAN, SKYRIZI, RINVOQ, ENTYVIO, REZDIFFRA, VEGZELMA.
Industry payments across CA — which companies pay providers there.
